On Wednesday, BofA Securities revised its price target for ProKidney Corp. (NASDAQ: PROK) shares, reducing it to $3.00 from the previous $4.00, while the Neutral rating on the stock remains unchanged. The adjustment comes in response to a recent financing event and considerations regarding the company's financial resources.
The firm's analysis points to a cash runway for ProKidney that is expected to fall short by approximately half a year from the crucial results of the company's REACT cell therapy treatment, which is being developed to slow or halt the progression of chronic kidney disease.
Despite acknowledging the substantial potential for peak sales, BofA Securities highlights the clinical risks and the possibility of further dilutive financing as factors that contribute to a balanced risk/reward profile for ProKidney's stock.
In addition, the firm has updated its model for ProKidney's second-quarter 2024 earnings per share (EPS), taking into account the increased share count following a public offering that took place in June 2024.
Moreover, the forecast for operating expenses beyond 2024 has been lowered, reflecting the discontinuation of the Phase 3 Proact-2 study. The specific adjustments made to the firm's financial model are outlined in Exhibit 1.
The reiteration of the Neutral rating by BofA Securities is based on the view that the upcoming year is expected to be light on significant events that could act as catalysts for the stock. This stance reflects a cautious optimism, tempered by the various challenges and uncertainties faced by the company.
In other recent news, ProKidney Corp. continues to make significant strides in its clinical trials and corporate operations. The biotech firm has refocused its Phase 3 clinical trial program, discontinuing the PROACT 2 trial outside the U.S. and concentrating on the PROACT 1 trial.
This strategic shift aims to expedite U.S. approval and commercial launch of rilparencel, its chronic kidney disease treatment candidate, and is expected to save the company an estimated $150 to $175 million.
Analyst firms BTIG and BofA Securities have maintained their respective Buy and Neutral ratings on ProKidney stock, following the company's strategic decision. BTIG has reduced its price target to $5 from $6, while BofA Securities maintains a steady price target of $4.
ProKidney has also launched a $125 million share offering to fund various corporate activities, including clinical trials and research and development. The company reported positive interim results from its Phase 2 REGEN-007 trial, demonstrating stabilization of kidney function in patients with chronic kidney disease caused by diabetes.
The company's cash is expected to support operating plans into the first quarter of 2027, following the strategic refocus of its Phase 3 program. ProKidney anticipates topline data from the PROACT 1 trial by the third quarter of 2027. These are recent developments for ProKidney Corp.
InvestingPro Insights
Adding to the analysis by BofA Securities, InvestingPro data suggests that ProKidney Corp. (NASDAQ: PROK) holds a market capitalization of $695.22 million, with a notable P/E ratio of -3.59, indicating that investors have been valuing the company despite its lack of profitability over the last twelve months. The company's performance has shown significant volatility, with a strong return of 8.6% over the last week and an impressive 44.58% over the last six months, yet it has experienced a steep price decline of 72.22% over the past year.
Two InvestingPro Tips that are particularly relevant to ProKidney's current situation include the fact that analysts have recently revised their earnings upwards for the upcoming period, which may signal a positive shift in expectations. Moreover, despite the challenges, ProKidney holds more cash than debt on its balance sheet, which could provide some financial stability in the near term. On the other hand, it's important to note that the company is quickly burning through cash, which aligns with BofA Securities' concerns about the cash runway and potential for further dilutive financing events.
For those interested in a deeper dive into ProKidney's financial health and future prospects, InvestingPro offers additional insights and tips. There are 12 more InvestingPro Tips available, providing a comprehensive analysis for investors seeking to make informed decisions. To explore these insights, visit https://www.investing.com/pro/PROK.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.